Pharmaceutical Manufacturing of Sulfamethoxazole and Trimethoprim Tablets

The contract involves the manufacture of Sulfamethoxazole and Trimethoprim Tablets, USP 400 mg/80 mg, strictly adhering to FDA USP standards and current Good Manufacturing Practices to ensure pharmaceutical quality and consistency. The production must also comply with military packaging specifications, indicating the final product is intended for government or defense use, with specific requirements for labeling, shielding, and distribution readiness. The work is categorized as a subcontract under NAICS code 325412, which corresponds to Pharmaceutical and Biological Product Manufacturing, and the place of performance is designated as Fort Campbell with a zip code of 42223-0000. The solicitation was posted on April 30, 2026, with a response deadline of May 6, 2026, and is managed by the Medical Supply Chain Pharm FSA under the Department of Defense. The contract is part of the broader defense pharmaceutical supply chain, emphasizing reliability and regulatory compliance for critical medications used in military healthcare settings. Although the solicitation number and point of contact are not provided, the reference to DIBBS indicates the procurement is administered through the Defense Logistics Agency’s electronic marketplace, suggesting a formal bid process with potential for multiple qualified vendors. The absence of a set-aside classification implies the opportunity is open to all eligible contractors, with selection based on compliance, capability, and cost-effectiveness. The timing of the solicitation suggests an advanced planning cycle aligned with defense procurement rhythms, requiring thorough documentation and readiness for audits or inspection by military quality assurance units.